ORCHESTRA BIOMED HOLDINGS IN
OBIONASDAQTrading Snapshot
- Day Range
- $4.36 – $4.43
- 52-Week Range
- $2.20 – $5.42
- Volume
- $2.70B
- Avg Volume
- $2.00B
- Shares Outstanding
- 59.9M
- Next Earnings
- Oct 14, 2026
Fundamentals Snapshot
- Annual Revenue
- $33M
- Last Q Revenue
- $88,000
- P/E Ratio
- —
- P/S Ratio
- 8.2x
- EPS (TTM)
- $-1.13
- Dividend Yield
- —
Why Investors Own OBIO
- ✓High-growth profile — revenue up +6.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 70% gross margin and 11% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About ORCHESTRA BIOMED HOLDINGS IN
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Piper Sandler Reiterates Overweight on Orchestra BioMed Hldgs, Raises Price Target to $10
Piper Sandler analyst Matt O'Brien reiterates Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight and raises the price target from $9 to $10.
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Misses Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of -8.57% and -32.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
The BACKBEAT global pivotal trial (“BACKBEAT Trial”), conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by end of Q3 2026, with primary data presentation targeted for Q2 2027, assuming those endpoints are met.Virtue pivotal trial is advancing with further site activations and patient enrollments. $110 million cash balance provides projected runway into Q4 2027 and through key upcoming milestones, following $35 million in strategic cap
Orchestra BioMed Hldgs Q2 EPS $(0.38) Misses $(0.37) Estimate, Sales $88.000K Miss $121.400K Estimate
Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.37) by 2.7 percent. This is a 24 percent increase over losses of $(0.50) per share
Rare Stock Picks In July 2026 - From 22 Discerning Analysts
In our monthly Rare Stock Picks series, we're highlighting July 2026 investment picks. Click here for the list of July 2026 Buy recommendations.
Orchestra BioMed: Nearing The First Of Two Pivotal Readouts
Orchestra BioMed nears pivotal trial readouts for AVIM Therapy & Virtue SAB, backed by Medtronic/Terumo. Click to see catalysts, valuation & upside.